Immix Biopharma, Inc.
NASDAQ: IMMX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ilya Rachman
- Employees
- 18
- Headquarters
- Los Angeles, United States
- IPO year
- 2021
- Market cap
- $546.2M
- Website
- https://www.immixbio.com
Loading IMMX…
Loading profile data…Frequently asked questions about IMMX
What does Immix Biopharma, Inc. (IMMX) do?
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials f...
Where does IMMX trade?
Immix Biopharma, Inc. (IMMX) trades on the NASDAQ Capital Market.
What sector is IMMX in?
Immix Biopharma, Inc. (IMMX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immix Biopharma, Inc.?
Ilya Rachman is the chief executive officer of Immix Biopharma, Inc. (IMMX).
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. is headquartered in United States.
Does IMMX pay a dividend?
Immix Biopharma, Inc. (IMMX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMX go public?
Immix Biopharma, Inc. (IMMX) completed its initial public offering in 2021.